Amgen Inc. (AMGN): Price and Financial Metrics
AMGN Price/Volume Stats
| Current price | $274.02 | 52-week high | $329.72 |
| Prev. close | $273.54 | 52-week low | $211.71 |
| Day low | $269.64 | Volume | 811,066 |
| Day high | $274.47 | Avg. volume | 2,818,877 |
| 50-day MA | $276.04 | Dividend yield | 3.35% |
| 200-day MA | $272.40 | Market Cap | 146.98B |
AMGN Stock Price Chart Interactive Chart >
Amgen Inc. (AMGN) Company Bio
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology. (Source:Wikipedia)
Latest AMGN News From Around the Web
Below are the latest news stories about AMGEN INC that investors may wish to consider to help them evaluate AMGN as an investment opportunity.
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca OnbodyThe FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. |
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study DataBristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively. |
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth KnowingIn the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day. |
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for LumakrasPer the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval. |
FDA Wants Another Amgen Study on LumakrasAmgen will need to run another confirmatory study to win full FDA approval of its lung-cancer drug Lumakras. Amgen says the FDA, which granted conditional approval to the drug in 2021, has turned away its application seeking full approval and called on the company to complete the additional study by February 2028. An FDA advisory panel in October raised issues with Amgen's previous confirmatory study, citing problems with how the study was conducted, its small size and relatively minor extension of the time that patients lived without their cancers getting worse. |
AMGN Price Returns
| 1-mo | -2.42% |
| 3-mo | -10.99% |
| 6-mo | 6.41% |
| 1-year | 15.67% |
| 3-year | 17.35% |
| 5-year | 75.95% |
| YTD | -4.12% |
| 2023 | 13.46% |
| 2022 | 20.43% |
| 2021 | 0.87% |
| 2020 | -1.99% |
| 2019 | 27.60% |
AMGN Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching AMGN
Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...